CGTX Market Update: 24‑Hour Gains, FDA Alignment on Dementia Trial & Stock Performance Snapshot

Cognition Therapeutics Inc. (CGTX) Market Update

• Trading Performance (24 h ending 03:42 PM CET, Thursday 22 Oct 2026)

• Price change: +1.77 %

• Current price: $0.77 per share on major exchanges

• Market Metrics

• Shares outstanding: 95.1 million

• Market capitalization: $71.2 million

• 24‑hour trading volume: $220.4 k

• 200‑day simple moving average: $1.09

• 52‑week high: $1.83 (31 Oct 2025)

• 52‑week low: $0.55 (30 Mar 2026)

• Performance Relative to Last Month

• Shares declined -23.85 % since the previous month’s close.

Recent Corporate Filing

On 22 Oct 2026, Cognition Therapeutics Inc. filed a Current Report with the Securities and Exchange Commission. Key points include:

1. FDA Alignment on Phase 3 Study

• The U.S. Food and Drug Administration issued written alignment on critical aspects of a Phase 3 trial for the investigational drug zervimesine in patients with dementia with Lewy bodies.
• The study design, patient selection criteria, dosing regimen, duration, and primary endpoints were detailed.
• Neuropsychiatric and functional outcomes will be primary assessment points.

2. Supplementary Documentation

• The filing incorporated the company’s accompanying press release and the latest financial statements.

No additional operational or financial disclosures were provided beyond the FDA alignment and the outlined study parameters.

Comparative Stock Performance (Last 24 h)

Additional Ratios:

• CPHC: P/E = 682.83
• SOTK: P/E = 44.5

Company Overview

• Name: Cognition Therapeutics, Inc.
• Headquarters: Pittsburgh, United States
• Business Focus: Discovery and development of small‑molecule therapeutics targeting toxic proteins implicated in cognitive decline, including Alzheimer’s disease and other neurodegenerative disorders.
• Global Presence: Operates worldwide through its official website (www.cogrx.com ) and is listed on the Nasdaq stock exchange.